Ask AI

An Interactive Case Challenge With Next-Generation Basal Insulin Therapies in T2D

Start Activity
Case Challenge
Case Challenge Start Activity
This activity is available for 1.00 CME/CE credit(s).

Released: September 30, 2026

Expiration: September 29, 2027

See Activity Collection

Step 1 of 5

1 Pre Assessment 2 Challenge 3 Post Assessment 4 Evaluation 5 Credit

This interactive patient case challenges learners to apply emerging evidence and practical decision-making principles for once-weekly basal insulin therapy in adults with T2D who remain above glycemic targets. Through a longitudinal case, learners evaluate persistent fasting hyperglycemia, treatment burden, adherence barriers, and patient preferences to determine when basal insulin initiation is appropriate and whether a once-weekly strategy may offer a practical alternative to daily therapy. The activity examines evidence-based dosing, titration, glucose monitoring, hypoglycemia risk, and distinctions between insulin-naive initiation and transition from daily basal insulin, while reinforcing shared decision-making, and strategies to support long-term treatment engagement.

Richard E. Pratley
Richard E. Pratley, MD
Insulin Interactive Case Challenge

Pre Assessment

Assess your current knowledge and clinical approach before beginning your Case Challenge.
Begin Your Case Challenge
1.

How many people with type 2 diabetes (T2D) do you provide care for in a typical week?

2.

For those who practice in academic or community settings, please indicate your practice setting:

3.

A 58-year-old man with T2D has an A1C of 8.1% despite metformin, an SGLT2 inhibitor, and a maximally tolerated GLP-1 receptor agonist (RA). His fasting glucose values are consistently 160-195 mg/dL. He works rotating shifts and frequently misses daily medications. He is willing to begin insulin but is concerned that another daily treatment will be difficult to sustain. He has no history of severe hypoglycemia and can reliably monitor his glucose. Which treatment plan most appropriately incorporates emerging evidence while addressing this patient’s needs?

4.

A 72-year-old man with T2D is transitioning from once-daily basal insulin to once-weekly insulin efsitora alfa. He also takes once-weekly tirzepatide. During education, he says, “Both pens are weekly, so I’ll keep them together and take whichever one I pick up first every Sunday.” Which intervention is most important before he begins the new regimen?

Begin Your Case Challenge